Literature DB >> 23347078

Risk factors associated with primary and secondary reduced libido in male patients with sexual dysfunction.

Giovanni Corona1, Giulia Rastrelli, Valdo Ricca, Emmanuele A Jannini, Linda Vignozzi, Matteo Monami, Alessandra Sforza, Gianni Forti, Edoardo Mannucci, Mario Maggi.   

Abstract

INTRODUCTION: Hypoactive sexual desire is defined as a persistent or recurrent deficient or absent sexual fantasies or desire for sexual activity that should not be comorbid with other medical conditions or with the use of psychoactive medications. Reduced libido is a symptom referring more to a reduction in sexual drive for sexual activity. AIM: To investigate the risk factors of primary reduced libido (i.e., not associated with conditions causing loss of libido such as hypogonadism, hyperprolactinemia, psychopathology, and/or psychoactive medications) or secondary reduced libido (i.e., with aforementioned conditions) in male patients with sexual dysfunction.
METHOD: A consecutive series of 3,714 men (mean age 53.2 ± 12.5 years) was retrospectively studied. MAIN OUTCOME MEASURES: Patient's reduced libido was evaluated using question #14 of structured interview for erectile dysfunction (SIEDY) ("Did you have more or less desire to make love in the last 3 months?").
RESULTS: Reduced libido was comorbid with erectile dysfunction, premature ejaculation, and delayed ejaculation in 38%, 28.2%, and 50%, respectively, whereas it was isolated in 5.1%. Reduced libido prevalence was substantially increased by hypogonadism, almost doubled by psychopathology and universally present in subjects with hyperprolactinemia (secondary reduced libido). Subjects with primary reduced libido are characterized by higher postschool qualification, more disturbances in domestic and dyadic relationships, and an overall healthy body (lower glycemia and triglyceride levels). Accordingly, in patients with primary reduced libido, the risk of major cardiovascular events as calculated with the Progetto Cuore algorithm was lower than in the rest of the sample. Features of hypogonadism- or psychopathology-associated reduced libido essentially reflect their underlying conditions. Comorbidity with other sexual dysfunctions did not affect the main characteristics of primary or secondary reduced libido.
CONCLUSIONS: Primary and secondary reduced libido have different risk factors and clinical characteristics. Recognizing primary or secondary reduced libido will help clinicians to identify comorbidities and to tailor appropriate treatments.
© 2013 International Society for Sexual Medicine.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23347078     DOI: 10.1111/jsm.12043

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  20 in total

Review 1.  The role of testosterone in male sexual function.

Authors:  Giovanni Corona; Mario Maggi
Journal:  Rev Endocr Metab Disord       Date:  2022-08-23       Impact factor: 9.306

2.  Management of premature ejaculation: a clinical guideline from the Italian Society of Andrology and Sexual Medicine (SIAMS).

Authors:  A Sansone; A Aversa; G Corona; A D Fisher; A M Isidori; S La Vignera; E Limoncin; M Maggi; M Merico; E A Jannini
Journal:  J Endocrinol Invest       Date:  2020-10-30       Impact factor: 4.256

3.  How to define hypogonadism? Results from a population of men consulting for sexual dysfunction.

Authors:  G Rastrelli; G Corona; M Tarocchi; E Mannucci; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-01-05       Impact factor: 4.256

4.  Gynecomastia in subjects with sexual dysfunction.

Authors:  E Maseroli; G Rastrelli; G Corona; V Boddi; A M L Amato; E Mannucci; G Forti; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-02-11       Impact factor: 4.256

Review 5.  The role of prolactin in andrology: what is new?

Authors:  Giulia Rastrelli; Giovanni Corona; Mario Maggi
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 6.  Erectile dysfunction and central obesity: an Italian perspective.

Authors:  Giovanni Corona; Giulia Rastrelli; Sandra Filippi; Linda Vignozzi; Edoardo Mannucci; Mario Maggi
Journal:  Asian J Androl       Date:  2014 Jul-Aug       Impact factor: 3.285

7.  Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors.

Authors:  Giovanni Corona; Carlo B Giorda; Domenico Cucinotta; Piero Guida; Elisa Nada
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

Review 8.  Risks and benefits of late onset hypogonadism treatment: an expert opinion.

Authors:  Giovanni Corona; Linda Vignozzi; Alessandra Sforza; Mario Maggi
Journal:  World J Mens Health       Date:  2013-08-31       Impact factor: 5.400

9.  Clinical correlates of enlarged prostate size in subjects with sexual dysfunction.

Authors:  Giovanni Corona; Mauro Gacci; Elisa Maseroli; Giulia Rastrelli; Linda Vignozzi; Alessandra Sforza; Gianni Forti; Edoardo Mannucci; Mario Maggi
Journal:  Asian J Androl       Date:  2014 Sep-Oct       Impact factor: 3.285

10.  Cabergoline in the Treatment of Male Orgasmic Disorder-A Retrospective Pilot Analysis.

Authors:  Adam B Hollander; Alexander W Pastuszak; Tung-Chin Hsieh; William G Johnson; Jason M Scovell; Christina K Mai; Larry I Lipshultz
Journal:  Sex Med       Date:  2016-03       Impact factor: 2.491

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.